Table 3.
ST (n=162) | CT (n=301) | CT vs. ST | ||||
---|---|---|---|---|---|---|
Attribute | CS-ST (n=98) | PS-ST (n=64) | CS-CT (n=185) | PS-CT (n=116) | p < | |
Patients | n (%) | n (%) | n (%) | n (%) | CS | PS |
Local disease-free | 11 (11.2) | 0 | 154 (83.2) | 0 | 4.8×10−16 | — |
Disease-free | 1 (1.0) | 0 | 136 (73.5) | 0 | 1.5×10−15 | — |
Metastasis-free: M0 | 43 (43.9) | 31 (48.4) | 165 (89.2) | 95 (81.9) | 1.8×10−15 | 6.5×10−6 |
Bearing metastasis: M1 | 55 (56.1) | 33 (51.6) | 20 (10.8) | 21 (18.1) | ||
M1 | ||||||
M0-1 | 49 (50.0) | 26 (40.6) | 9 (4.9) | 9 (7.8) | 0.00018 | 0.00968 |
M1-1 | 6 (6.1) | 7 (10.9) | 11 (6.0) | 12 (10.3) | ||
Alive | 0 | 0 | 54 (29.2) | 21 (18.1) | — | — |
Dropped out treatment | 0 | 0 | 13 (7.0) | 5 (4.3) | — | — |
Death | 98 (100) | 64 (100) | 118 (63.8) | 90 (77.6) | — | — |
Cause of death | CS-ST (n=98) | PS-ST (n=64) | CS-CT (n=118) | PS-CT (n=90) | p < | |
Patients | n (%) | n (%) | n (%) | n (%) | CS | PS |
Local disease (LD) | 42 (42.9) | 31 (48.4) | 31 (26.3) | 62 (68.9) | 0.01384 | 0.01250 |
Metastases (M) | 55 (56.1) | 33 (51.6) | 18 (15.3) | 21 (23.3) | 2.4×10−10 | 0.00054 |
Disease (LD+M) | 97 (99.0) | 64 (100) | 49 (41.6) | 83 (92.2) | 6.1×10−16 | 0.04182 |
Unrelated diseases | 1 (1.0) | 0 (0) | 69 (58.5) | 7 (7.8) |
CR, complete response; disease-free patients, dead or alive patients without any evidence of disease at the end of the study; local disease-free patients, patients that did not display postsurgical relapse at the end of the study after one or more complete (CS) or partial (PS) surgeries; M0, patients free of distant metastasis all along the treatment; M0-1, dogs that developed distant metastasis during the treatment; M1, animals bearing distant metastases at the end of the treatment; M1-1, patients with distant metastases all along the treatment.
Patients were clinically evaluated and treated as described in Materials and Methods. p-Values were calculated by two-tailed Fisher's exact test.